Novel neurosteroid drug candidates for the treatment of chemotherapy-induced painful neuropathies

Analogs of the natural non-toxic allopregnanolone to eradicate neuropathic pain with expected reduced side-effects

KEYWORDS

Neuropathic pain
Chemotherapy
Cancer

PATENTS

FR 1152390
23/03//2011
WO/2012/127176
filed on 23/03/12
National phases:
EP,US

INVENTORS

Mensah G.
Meyer L.
Patte-Mensah C.
Taleb O.
Miesch M.
Geoffrey P.
Ressault B.
Strasbourg (France)
EA 4438 (Unistra)
UMR 7177 (Unistra-CNRS)

TECHNOLOGY

- Based on Lab findings that the natural neurosteroid allopregnanolone, devoted on toxic side-effects in human, prevents and eradicates neuropathic symptoms evoked in rats by VINC and OXAL
- Identification of chemically optimized analogs that display a potent neuroprotective effect without proliferative action on human neuroblastoma SHSY5 cells

APPLICATIONS

- Prevention and treatment of painful neuropathies
- In combination to cancer chemotherapy to prevent/suppress drug-evoked neuropathies

INNOVATION ADVANTAGES

- Novel MOA preventing and repairing lesions responsible for neuropathic pain
- Expected to be safe, as analogs of the allopregnanolone

DEVELOPMENT STATUS

- First *in vivo* POC in VINC-induced allodynia rat model
- Ongoing determination of PD parameters and non-toxic profile after oral administration in various animal models (prophylactic and therapeutic indication)

Partnership *: Seeking partners to license the technology or to enter the co-conception program*

OT_MENSAH_20140611

Parc d'Innovation
650 Bd Gonthier d'Andernach
67400 ILLKIRCH - FRANCE
www.satt.conectus.fr

CONTACT
Nathalie Lenne
Business Developer, Healthcare
Phone: +33 (0)6 09 79 06 13 - nathalie.lenne@satt.conectus.fr